Predicting efficacy of sunitinib in metastatic renal cell carcinoma

References

• Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009;10(8):757–763.
   PubMed Web of Science ®Google Scholar
• Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34(3):193–205.
   PubMed Web of Science ®Google Scholar
• Cheng L, Zhang S, MacLennan GT, Lopez-Beltran A, Montironi R. Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. Hum Pathol. 2009;40(1):10–29.
   PubMed Web of Science ®Google Scholar
• Dhote R, Thiounn N, Debré B, Vidal-Trecan G. Risk factors for adult renal cell carcinoma. Urol Clin North Am. 2004;31(2):237–247.
   Web of Science ®Google Scholar
• Kovacs G, Brusa P, De Riese W. Tissue-specific expression of a constitutional 3;6 translocation: development of multiple bilateral renal-cell carcinomas. Int J Cancer. 1989;43(3):422–427.
   Web of Science ®Google Scholar
• Peruzzi B, Athauda G, Bottaro DP. The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells. Proc Natl Acad Sci U S A. 2006;103(39):14531–14536.
   Web of Science ®Google Scholar
• Melillo G. Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev. 2007;26(2):341–352.
   PubMed Web of Science ®Google Scholar
• Semenza GL. Hypoxia-inducible factor 1 and cancer pathogenesis. IUBMB Life. 2008;60(9):591–597.
   PubMed Web of Science ®Google Scholar
• Mathew A, Devesa SS, Fraumeni JF, Chow W-H. Global increases in kidney cancer incidence, 1973–1992. Eur J Cancer Prev. 2002;11(2):171–178.
   PubMed Web of Science ®Google Scholar
• Clegg LX, Reichman ME, Miller BA, et al. Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control. 2009;20(4):417–435.
   PubMed Web of Science ®Google Scholar
• [No authors listed]. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet. 1999;353(9146):14–17.
   Web of Science ®Google Scholar
• Vogelzang NJ. Treatment options in metastatic renal carcinoma: an embarrassment of riches. J Clin Oncol. 2006;24(1):1–3.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–456.
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349(5):427–434.
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–134.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–124.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer. 2013;49(6):1287–1296.
   PubMed Web of Science ®Google Scholar
• Carmichael C, Lau C, Josephson DY, Pal SK. Comprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma. Clin Adv Hematol Oncol. 2012;10(5):307–314.
   PubMedGoogle Scholar
• Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–2281.
   PubMed Web of Science ®Google Scholar
• Choueiri TK. Clinical treatment decisions for advanced renal cell cancer. J Natl Compr Canc Netw. 2013;11(5S):694–697.
   Google Scholar
• Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22(3):454–463.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Bukowski R, et al. Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. Br J Cancer. 2013;108(12):2470–2477.
   PubMed Web of Science ®Google Scholar
• Heng DYC, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–5799.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584–3590.
   PubMed Web of Science ®Google Scholar
• O’Brien MF, Russo P, Motzer RJ. Sunitinib therapy in renal cell carcinoma. BJU Int. 2008;101(11):1339–1342.
   Web of Science ®Google Scholar
• Park W-H, Eisen T. Prognostic factors in renal cell cancer. BJU Int. 2007;99(5 Pt B):1277–1281.
   Web of Science ®Google Scholar
• Schmidinger M, Larkin J, Ravaud A. Experience with sunitinib in the treatment of metastatic renal cell carcinoma. Ther Adv Urol. 2012;4(5):253–265.
   Google Scholar
• George S, Reichardt P, Lechner T, Li S, Cohen DP, Demetri GD. Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib. Ann Oncol. 2012;23(12):3180–3187.
   PubMed Web of Science ®Google Scholar
• Rini BI, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2011;103(9):763–773.
   PubMed Web of Science ®Google Scholar
• Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007;99(1):81–83.
   PubMedGoogle Scholar
• Ravaud A, Schmidinger M. Clinical biomarkers of response in advanced renal cell carcinoma. Ann Oncol. 2013;24(12):2935–2942.
   PubMed Web of Science ®Google Scholar
• Wolter P, Stefan C, Decallonne B, et al. Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC). J Clin Oncol. 2008:26(Suppl 15):5126.
   Web of Science ®Google Scholar
• Sabatier R, Eymard JC, Walz J, et al. Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma? Ann Oncol. 2012;23(3):714–721.
   PubMed Web of Science ®Google Scholar
• Puzanov I, Michaelson MD, Cohen DP, Li S, Burnett P, Desai J. Evaluation of hand-foot syndrome (HFS) as a potential biomarker of sunitinib (SU) efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumor (GIST). Eur J Cancer. 2011;47:Abstr 1444.
   Google Scholar
• Donskov F, Michaelson MD, Puzanov I, et al. Comparative assessment of sunitinib-associated adverse events (AEs) as potential biomarkers of efficacy in metastatic renal cell carcinoma (mRCC). Ann Oncol. 2012:23 Suppl 9:Abstr 785O.
   Web of Science ®Google Scholar
• McDermott DF, Atkins MB. Immune therapy for kidney cancer: a second dawn? Semin Oncol. 2013;40(4):492–498.
   Web of Science ®Google Scholar
• Yang B, Gu W, Peng B, et al. High level of circulating endothelial progenitor cells positively correlates with serum vascular endothelial growth factor in patients with renal cell carcinoma. J Urol. 2012;188(6):2055–2061.
   Web of Science ®Google Scholar
• Vroling L, van der Veldt AA, de Haas RR, et al. Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. Angiogenesis. 2009;12(1):69–79.
   Web of Science ®Google Scholar
• Rossi E, Fassan M, Aieta M, et al. Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to sunitinib in metastatic renal cancer. Br J Cancer. 2012;107(8):1286–1294.
   Web of Science ®Google Scholar
• Gruenwald V, Beutel G, Schuch-Jantsch S, et al. Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib. BMC Cancer. 2010;10(1):695.
   Google Scholar
• Powles T, Chowdhury S, Shamash J, et al. Increased haematopoietic progenitor cells are associated with poor outcome in patients with metastatic renal cancer treated with sunitinib. Ann Oncol. 2011;22(4):815–820.
   Web of Science ®Google Scholar
• Choueiri TK, ;Vaziri SA, ;Jaeger E, et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol. 2008;180(3):860–866.
   PubMed Web of Science ®Google Scholar
• Kim J, Hwang J, Jeong H, et al. Promoter methylation status of VEGF receptor genes: a possible epigenetic biomarker to anticipate the efficacy of intracellular-acting VEGF-targeted drugs in cancer cells. Epigenetics. 2012;7(2):191–200.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008;26(33):5352–5359.
   PubMed Web of Science ®Google Scholar
• Takahashi A, Sasaki H, Kim SJ, et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res. 1994;54(15):4233–4237.
   PubMed Web of Science ®Google Scholar
• Deprimo SE, Bello CL, Smeraglia J, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med. 2007;5:32.
   PubMed Web of Science ®Google Scholar
• Kjeldsen L, Johnsen AH, Sengeløv H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem. 1993;268(14):10425–10432.
   PubMed Web of Science ®Google Scholar
• Porta C, Paglino C, De Amici M, et al. Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int. 2010;77(9):809–815.
   PubMed Web of Science ®Google Scholar
• Sakai I, Miyake H, Fujisawa M. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation. BJU Int. 2013;112(2):E211–E220.
   Web of Science ®Google Scholar
• Lieu C, Heymach J, Overman M, Tran H, Kopetz S. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res. 2011;17(19):6130–6139.
   PubMed Web of Science ®Google Scholar
• Trikha M, Corringham R, Klein B, Rossi J-F. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res. 2003;9(13):4653–4665.
   PubMed Web of Science ®Google Scholar
• Nakaigawa N, Yao M, Baba M, et al. Inactivation of von Hippel-Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma. Cancer Res. 2006;66(7):3699–3705.
   PubMed Web of Science ®Google Scholar
• Porta C, Paglino C, Imarisio I, et al. Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients. Oncology. 2013;84(2):115–122.
   PubMed Web of Science ®Google Scholar
• Perez-Gracia JL, Prior C, Guillén-Grima F, et al. Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. Br J Cancer. 2009;101(11):1876–1883.
   Web of Science ®Google Scholar
• Fujita T, Iwamura M, Ishii D, et al. C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib. Int J Urol. 2012;19(10):908–913.
   PubMed Web of Science ®Google Scholar
• Papazisis KT, Kontovinis LF, Papandreou CN, et al. Brain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinoma. BMC Cancer. 2010;10:489.
   Web of Science ®Google Scholar
• Radu A, Pichon C, Camparo P, et al. Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med. 2010;363(17):1621–1630.
   PubMed Web of Science ®Google Scholar
• Siraj MA, Pichon C, Radu A, Ghinea N. Endothelial follicle stimulating hormone receptor in primary kidney cancer correlates with subsequent response to sunitinib. J Cell Mol Med. 2012;16(9):2010–2016.
   PubMed Web of Science ®Google Scholar
• Escudier B, Szczylik C, Porta C, Gore M. Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat Rev Clin Oncol. 2012;9(6):327–337.
   PubMed Web of Science ®Google Scholar
• Porta C, Szczylik C, Escudier B. Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical review. Crit Rev Oncol Hematol. 2012;82(3):323–337.
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Choueiri TK, Escudier B, et al. Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? Eur Urol. 2012;61(2):307–316.
   PubMed Web of Science ®Google Scholar